InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.62
(
-0.07%
)
US TECH 100
18,987.20
(
-1.15%
)
Dow Jones
39,416.31
(
0.68%
)
Brent Oil
85.26
(
1.47%
)
Bitcoin
60,267.44
(
-4.58%
)
Post# of 252326
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119904
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 115567

Saturday, 02/26/2011 4:49:24 PM

Saturday, February 26, 2011 4:49:24 PM

Post# of 252326

MRX—Did you listen to the latest CC? I believe this was mentioned.

Please listen to the CC answer to the question you just posted, which is that Ranbaxy has first-filer status on the 105mg dose.

Why would MRX settle with NVS if it is not the first-to-file on the 105mg dose?

From MRX’s perspective, it was important to settle with all generic challengers. Note that the determination of which company is ultimately awarded first-filer status on a given dosage is not always known by the branded-drug company at the time a settlement is struck.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up